Structure Therapeutics American Stock Market Value
| GPCR Stock | 36.97 1.73 4.47% |
| Symbol | Structure |
Structure Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Structure Therapeutics. If investors know Structure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Structure Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.19) | Return On Assets (0.13) | Return On Equity (0.18) |
The market value of Structure Therapeutics is measured differently than its book value, which is the value of Structure that is recorded on the company's balance sheet. Investors also form their own opinion of Structure Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Structure Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Structure Therapeutics' market value can be influenced by many factors that don't directly affect Structure Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Structure Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Structure Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Structure Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Structure Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Structure Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Structure Therapeutics.
| 10/14/2024 |
| 11/13/2024 |
If you would invest 0.00 in Structure Therapeutics on October 14, 2024 and sell it all today you would earn a total of 0.00 from holding Structure Therapeutics American or generate 0.0% return on investment in Structure Therapeutics over 30 days. Structure Therapeutics is related to or competes with Day One, X4 Pharmaceuticals, Inozyme Pharma, Acumen Pharmaceuticals, Mereo BioPharma, Terns Pharmaceuticals, and Amylyx Pharmaceuticals. Structure Therapeutics is entity of United States More
Structure Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Structure Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Structure Therapeutics American upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.88 | |||
| Information Ratio | 0.0165 | |||
| Maximum Drawdown | 21.24 | |||
| Value At Risk | (4.47) | |||
| Potential Upside | 8.03 |
Structure Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Structure Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Structure Therapeutics' standard deviation. In reality, there are many statistical measures that can use Structure Therapeutics historical prices to predict the future Structure Therapeutics' volatility.| Risk Adjusted Performance | 0.0554 | |||
| Jensen Alpha | 0.1003 | |||
| Total Risk Alpha | (0.55) | |||
| Sortino Ratio | 0.0214 | |||
| Treynor Ratio | 0.2914 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Structure Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Structure Therapeutics Backtested Returns
Currently, Structure Therapeutics American is not too volatile. Structure Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0231, which indicates the firm had a 0.0231% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Structure Therapeutics American, which you can use to evaluate the volatility of the company. Please validate Structure Therapeutics' Coefficient Of Variation of 1620.03, semi deviation of 2.71, and Risk Adjusted Performance of 0.0554 to confirm if the risk estimate we provide is consistent with the expected return of 0.0863%. Structure Therapeutics has a performance score of 1 on a scale of 0 to 100. The entity has a beta of 0.76, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Structure Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Structure Therapeutics is expected to be smaller as well. Structure Therapeutics right now has a risk of 3.74%. Please validate Structure Therapeutics value at risk, as well as the relationship between the skewness and day median price , to decide if Structure Therapeutics will be following its existing price patterns.
Auto-correlation | 0.63 |
Good predictability
Structure Therapeutics American has good predictability. Overlapping area represents the amount of predictability between Structure Therapeutics time series from 14th of October 2024 to 29th of October 2024 and 29th of October 2024 to 13th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Structure Therapeutics price movement. The serial correlation of 0.63 indicates that roughly 63.0% of current Structure Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.63 | |
| Spearman Rank Test | 0.37 | |
| Residual Average | 0.0 | |
| Price Variance | 1.56 |
Structure Therapeutics lagged returns against current returns
Autocorrelation, which is Structure Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Structure Therapeutics' stock expected returns. We can calculate the autocorrelation of Structure Therapeutics returns to help us make a trade decision. For example, suppose you find that Structure Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Structure Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Structure Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Structure Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Structure Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Structure Therapeutics Lagged Returns
When evaluating Structure Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Structure Therapeutics stock have on its future price. Structure Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Structure Therapeutics autocorrelation shows the relationship between Structure Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Structure Therapeutics American.
Regressed Prices |
| Timeline |
Pair Trading with Structure Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Structure Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Structure Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Structure Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Structure Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Structure Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Structure Therapeutics American to buy it.
The correlation of Structure Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Structure Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Structure Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Structure Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.